# A Study to Test the Cardiac Effects of Padsevonil in Healthy Study Participants

> **NCT04126343** · PHASE1 · TERMINATED · sponsor: **UCB Biopharma S.P.R.L.** · enrollment: 54 (actual)

## Conditions studied

- Healthy Study Participants

## Interventions

- **DRUG:** Padsevonil
- **DRUG:** Moxifloxacin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04126343
- **Lead sponsor:** UCB Biopharma S.P.R.L.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-23
- **Primary completion:** 2020-05-22
- **Final completion:** 2020-05-22
- **Target enrollment:** 54 (ACTUAL)
- **Why stopped:** Based on available data, UCB has decided to stop development of padsevonil as adjunctive treatment of focal-onset seizures
- **Last updated:** 2021-06-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04126343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04126343, "A Study to Test the Cardiac Effects of Padsevonil in Healthy Study Participants". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT04126343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*